GLP-1 receptor agonists show promise beyond weight loss, impacting cardiovascular health, insulin resistance, and quality of life, particularly for high-risk patients.
February marks American Heart Month in the United States, a time dedicated to raising awareness about cardiovascular diseases, which remain the leading cause of death globally. In line with this mission, Endocrine News emphasizes recent journal studies examining the effects of incretin-based therapies in relation to obesity and cardiovascular health, as well as their influences on liver function, quality of life, and insulin resistance. This month provides a relevant opportunity to discuss several studies investigating various aspects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and similar incretin therapies, given the significant implications of obesity on cardiovascular well-being.
Recent advances in obesity pharmacotherapy have led to remarkable efficacy in both weight reduction and improvements in cardiometabolic health. GLP-1RAs, together with other agonists targeting key metabolic regulators, are proving particularly effective for patients struggling with obesity-related cardiovascular and metabolic issues, delivering combined benefits that extend beyond simple weight loss. However, the situation is not without challenges, as a notable number of patients discontinue their treatment within the first year due to issues related to cost, accessibility, and tolerability. Nevertheless, research indicates that these therapies hold substantial promise for high-risk populations that have often faced barriers to aggressive treatment.
To summarize key findings:
A recent publication in Endocrinology highlighted novel dual and triple agonists that target GLP-1, GIP (glucose-dependent insulinotropic polypeptide), glucagon, and GDF15 for the management of type 2 diabetes and obesity. Chao Zheng, PhD, along with a team from The Second Affiliated Hospital of Zhejiang University's School of Medicine, has illuminated the potential expansions of patient populations that may benefit from these innovative peptide-based therapies, recognizing that traditional GLP-1RAs have limited efficacy for a substantial percentage of patients.
Currently, it is premature for healthcare professionals to adopt these new agents into routine clinical practice. However, the researchers provide a comprehensive review of what is known about dual and triple agonists targeting GIP, glucagon, and/or GDF15 alongside GLP-1. Importantly, the sustained action of specific GIP receptor (GIPR) agonists can suppress appetite and enhance insulin secretion, paving the way for the co-agonist tirzepatide. Comparative potency and effectiveness highlight tirzepatide's advantage over single GLP-1RAs like semaglutide and stimulate ongoing exploration in combined therapy.
The promise shown by dual and triple incretin-based agonists could dramatically improve treatment outcomes for the intertwined conditions of type 2 diabetes and obesity, along with their associated cardiovascular and other comorbidities. These multitarget therapies strive to create synergistic effects across various metabolic pathways governing appetite control, insulin secretion, liver metabolism, and energy expenditure, leading to broader metabolic enhancements than therapies focused on a single receptor type. For instance, a combination of GLP-1 with glucagon is intended to merge the appetite-suppressant and glucose-regulating benefits of GLP-1 with the lipolytic and thermogenic properties of glucagon.
Initial trials of new combination therapies indicate favorable outcomes, such as cotadutide—a daily injectable that reportedly improves liver metabolism and decreases HbA1c levels while demonstrating protective effects on kidney function, like a reduced albumin-to-creatinine ratio. Efinopegdutide has also been noted for its dose-dependent weight loss efficacy, potentially reducing liver fat more effectively than semaglutide, although it has been associated with a higher incidence of adverse events and less consistent efficacy concerning glycemic control.
Another agent, bamadutide, has shown meaningful improvements in both weight and glycemic outcomes, sometimes surpassing liraglutide in effectiveness, although it appears to favor GLP-1R activity over other mechanisms. Numerous additional dual agonists, including survodutide, mazdutide, and pemvidutide, show promising results in terms of weight management and cardiovascular benefits.
The dual agonists GLP-1R and GIPR, such as tirzepatide, seem to improve glycemic stability by increasing insulin secretion, curtailing glucagon levels, and decelerating gastric emptying, while potentially augmenting satiety through central pathways. Triple agonists that combine GLP-1, GIP, and glucagon target an even broader range of metabolic effects. Retatrutide, for example, indicated substantial reductions in HbA1c and weight while suggesting benefits for decreasing hepatic fat and improving biomarkers associated with metabolic dysfunction-related steatotic liver disease (MASLD). Further investigational agents, such as efocipegtrutide, show potential advantages in addressing obesity, MASLD/fibrosis, dyslipidemia, and neuroinflammation as demonstrated in preclinical studies.
Despite the substantial promise demonstrated in both preclinical and clinical investigations, these novel agents encounter challenges that warrant careful consideration. Complex mechanisms, uncertainties regarding long-term safety, and the requirement for acute optimization in dosing strategies are all identified areas that need additional exploration. Future research utilizing personalized methods anchored in patient-specific biomarkers may maximize the therapeutic benefits of these approaches.
In the study titled “Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program,” published in JACC: Heart Failure, Dr. Ambarish Pandey and his team showcased the efficacy of semaglutide among individuals battling heart failure with preserved ejection fraction (HFpEF) and frailty. This research, which involved 1,145 participants from the STEP-HFpEF trial, sought to investigate concerns about semaglutide's influence on frail patients. Dr. Pandey noted that the trial's composition revealed that more than 60% of participants were classified as 'most frail.' This statistic prompted critical inquiry into whether a treatment known for its weight loss effects—potentially exacerbating muscle loss—was suitable for such a population.
The findings suggest that semaglutide's benefits extend beyond mere weight loss. It positively impacts inflammatory responses and improves cardiac hemodynamics, offering additional metabolic advantages. In the context of obesity-related HFpEF, characterized by inflammation and metabolic dysfunction, semaglutide appears to be a fitting treatment choice. While an overall weight reduction of approximately 8% to 9% was expected compared to placebo, the most significant takeaway was semaglutide's ability to alleviate frailty burden (with varying efficacy according to frailty strata).
Dr. Pandey remarked on the noticeable improvements in symptoms particularly among the most frail individuals, indicating that the benefits extended far beyond weight loss. The overlapping biological mechanisms shared by obesity-related HFpEF and frailty—such as chronic inflammation and metabolic decline—suggest that semaglutide may effectively address these interconnected issues. Furthermore, emerging evidence implies that GLP-1RAs might improve muscle quality by decreasing fat deposits within muscle tissue. Since frail patients typically exhibit the most significant dysfunction, they have the most to gain from these interventions.
Remarkably, patients receiving semaglutide exhibited an 11-point improvement on the Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score after one year—a considerable enhancement that signifies a transition into a less frail category for many participants. Dr. Pandey emphasized the importance of these changes, highlighting that they greatly affect patients' everyday lives.
Overall, these findings suggest that semaglutide may not just manage symptoms; it has the potential to alter the very course of the disease, representing a significant shift in therapeutic strategies for patients with obesity-related HFpEF.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.